dr. horn on updated data from impower133 in small cell lung cancer
Published 4 years ago • 286 plays • Length 1:22Download video MP4
Download video MP3
Similar videos
-
1:50
small cell lung cancer: interpreting data from impower133
-
1:08
dr. horn on the fda approval of atezolizumab plus bevacizumab and chemotherapy in nsclc
-
7:20
small-cell lung cancer: the impower133 and caspian trials
-
6:33
a win for small–cell lung cancer: impower 133
-
1:07
dr. horn on the role of mobocertinib in nsclc
-
1:12
dr. horn discusses next steps with atezolizumab in sclc
-
5:23
atezolizumab carboplatin/etoposide for extensive-stage small cell lung cancer: impower133 update
-
1:50
impower133: atezolizumab, carboplatin plus etoposide for sclc
-
8:11
first-line immunotherapy: impower133 regimen
-
2:43
dr. bunn on immunotherapy advances in small cell lung cancer
-
9:24
impower010 supports adjuvant atezolizumab in early-stage nsclc | heather wakelee
-
14:00
asco 2021 lung recap: impower010: atezolizumab after chemo in non-small cell lung cancer
-
1:02
dr. rudin on the design of the keynote-604 trial in es-sclc
-
3:00
small-cell lung cancer: future directions in care
-
3:36
highlights from wclc 2018: nelson, alta, impower133 & pacific
-
4:52
targeting the immune system in non-small cell lung cancer
-
1:03
sangeetha palakurthi on fda approval of atezolizumab in nsclc
-
1:40
dr. piotrowska on eligibility criteria for osimertinib in lung cancer treatment
-
0:56
dr. ramalingam on treatment parameters for osimertinib in lung cancer